Healiva expands chronic wound treatment portfolio

Healiva is adding two innovative cell therapy products to its offering of treatment options for the care of acute and chronic wounds: EpiDex and healiva 002. According to a press release, the biotech company from the Swiss canton of Ticino formed in 2020 plans to establish “one of the world’s broadest portfolios of affordable, personalized, end-to-end wound care”.

Valerio Maria Ferrari, co-founder of Healiva and Chairman of the Bioseutica Group, comments: “With 36 million people worldwide currently suffering from chronic wounds, we urgently need novel solutions for hard-to-treat wounds.” Healiva Founder and CEO Priyanka Dutta-Passecker states that by acquiring these two “pioneering technologies” from Smith+Nephew, Healiva will be able to continue its rapid growth “by progressing to commercialization within four years of founding”.

EpiDex, an autologous skin equivalent formed of epidermis, can be used without any surgery needed to treat chronic venous leg ulcers. It has already received marketing authorization for Switzerland. As such, Healiva expects a rapid relaunch there as well as in Germany and other EMEA countries.

Healiva 002 is an allogenic cell product that has already demonstrated clinical success in testing. According to the information provided, Healiva plans to improve it further, scale up the manufacturing process, and continue with clinical development.